长效GLP—1受体激动药索马鲁肽治疗2型糖尿病疗效和安全性的系统评价(6)
[19] FONSECA V，CAPEHORN M，GARG S，et al. Semaglutide-induced reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes (SUSTAIN 1-3)[J]. Diabetologia，2017.DOI：10.1007/s00125-017-4350-z.
[20] MATHEUS AS，TANNUS LR，COBAS RA，et al. Impact of diabetes on cardiovascular disease：an update[J]. Int J Hypertens，2013.DOI：10.1155/2013/653789.
[21] SISTI LG，DAIKO M，CAMPANELLA P，et al. The effect of multifactorial lifestyle interventions on cardiovascular risk factors：a systematic review and meta-analysis of trials conducted in the general population and high risk groups[J]. Prev Med，2017.DOI：10.1016/j.ypmed.2017.12. 027.
[22] ZINMAN B，WANNER C，LACHIN JMD，et al. Empagliflozin，cardiovascular outcomes，and mortality in type 2 diabetes[J]. N Engl J Med，2015，373(22)：2117-2128.
[23] MARSO SP，DANIELS GH，BROWN FK，et al. Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med，2016，375(4)：311-322.
(收稿日期：2018-10-22 修回日期：2018-11-27)
(編辑：刘明伟), http://www.100md.com(芦志伟 孙浩 李莹 肖茏珂 董艳 刘爱娜 赵振宇)
[20] MATHEUS AS，TANNUS LR，COBAS RA，et al. Impact of diabetes on cardiovascular disease：an update[J]. Int J Hypertens，2013.DOI：10.1155/2013/653789.
[21] SISTI LG，DAIKO M，CAMPANELLA P，et al. The effect of multifactorial lifestyle interventions on cardiovascular risk factors：a systematic review and meta-analysis of trials conducted in the general population and high risk groups[J]. Prev Med，2017.DOI：10.1016/j.ypmed.2017.12. 027.
[22] ZINMAN B，WANNER C，LACHIN JMD，et al. Empagliflozin，cardiovascular outcomes，and mortality in type 2 diabetes[J]. N Engl J Med，2015，373(22)：2117-2128.
[23] MARSO SP，DANIELS GH，BROWN FK，et al. Liraglutide and cardiovascular outcomes in type 2 diabetes[J]. N Engl J Med，2016，375(4)：311-322.
(收稿日期：2018-10-22 修回日期：2018-11-27)
(編辑：刘明伟), http://www.100md.com(芦志伟 孙浩 李莹 肖茏珂 董艳 刘爱娜 赵振宇)